Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02843074
Title Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
Center for Cancer and Blood Disorders Bethesda Maryland 20817 United States Details
HCA Midwest Health/Research Medical Center Kansas City Missouri 64132 United States Details
Nebraska Methodist Hospital Omaha Nebraska 68114 United States Details
Tennessee Oncology Chattanooga Tennessee 37404 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field